MedTrace Logo

Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM

NCT06099912 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 131

Last updated 2026-02-12

No results posted yet for this study

Summary

Frailty is dynamic and confers poor outcomes in elderly patients with newly diagnosed multiple myeloma (NDMM), mainly because of the high prevalence of treatment discontinuation due to intolerability. We designed a multi-center prospective study (DynaFiT) based on our real-life practice to evaluate the feasibility and benefits of a dynamic frailty-tailored therapy in elderly patients with different fitness/frailty statuses.

Since Dara-based treatment have recently become the new standard regimens, in this amendment of the study, daratumumab added to VRd is recommended as induction therapy regimen.

Conditions

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • Second Hospital of Shanxi Medical University

    collaborator OTHER

  • The First Affiliated Hospital of Air Force Medicial University

    collaborator OTHER

  • FengYan Jin

    lead OTHER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-08
Primary Completion
2026-09-08
Completion
2029-09-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06099912 on ClinicalTrials.gov